Cosmo Pharmaceuticals (OTCMKTS:CMOPF – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 34,276 shares, an increase of 64.9% from the September 30th total of 20,782 shares. Based on an average trading volume of 1,281 shares, the short-interest ratio is currently 26.8 days.
Cosmo Pharmaceuticals Stock Performance
Shares of Cosmo Pharmaceuticals stock opened at C$66.08 on Tuesday. Cosmo Pharmaceuticals has a 1 year low of C$59.02 and a 1 year high of C$169.90. The business has a 50-day moving average of C$66.67 and a two-hundred day moving average of C$97.09.
Cosmo Pharmaceuticals Company Profile
Cosmo Pharmaceuticals N.V. is an international pharmaceutical company focused on developing, manufacturing and commercializing treatments for gastrointestinal and dermatological conditions. The company uses its proprietary MMX drug-delivery technology to formulate therapies designed to release active ingredients at targeted locations in the gastrointestinal tract.
Cosmo’s gastrointestinal portfolio includes products for inflammatory bowel disease and other digestive disorders, including mesalamine-based therapies and rifamycin-based treatments.
Recommended Stories
- Five stocks we like better than Cosmo Pharmaceuticals
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
